Drug Trial Radar · NCT03121586
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
995
Actual
Start
Jan 2017
Primary completion
Apr 30, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
Conditions
- Schizophrenia
Interventions
PimavanserinDrug
Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse EventsTime frame: Treatment period (52 weeks) and follow-up period (30 days): planned total of 56 weeks. Since the study was prematurely terminated, the reporting period was shortened; AEs were assessed to the end of treatment, at a mean duration of 319 days (or 46 weeks).
Locations
161 sites in 14 countries. Site status is shown where the registry gives one.
171-Alea Research Institute
Phoenix, Arizona
156-Woodland International Research Group, LLC
Little Rock, Arkansas
111-Woodland Research Northwest, LLC
Rogers, Arkansas
167-CITrials - Bellflower
Bellflower, California
105-ProScience Research Group
Culver City, California
123-Synergy San Diego
Lemon Grove, California
164-Artemis Institute for Clinical Research
San Diego, California
165-CITrials
Santa Ana, California
108-Collaborative Nueroscience Network, LLC
Torrance, California
125-Galiz Research
Hialeah, Florida
137-Innovative Clinical Research, Inc.
Lauderhill, Florida
146-Premier Clinical Research Institute, Inc.
Miami, Florida
162-Synexus Clinical Research, Inc.
Atlanta, Georgia
168-Atlanta Center for Medical Research
Atlanta, Georgia
102-Northwest Behavioral Research Center
Marietta, Georgia
114-Northwestern University
Chicago, Illinois
101-American Medical Research
Chicago, Illinois
130-Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois
118-Lake Charles Clinical Trials
Lake Charles, Louisiana
124-Altea Research Institute
Las Vegas, Nevada
141-Hassman Research Institute
Berlin, New Jersey
153-Albuquerque Neuroscience Inc.
Albuquerque, New Mexico
104-Neurobehavioral Research, Inc.
Cedarhurst, New York
140-Synexus Clinical Research, Inc - 140
Jamaica, New York
128-Finger Lakes Clinical Research
Rochester, New York
106-New Hope Clinical Research
Charlotte, North Carolina
145-Carolina Behavioral Care
Durham, North Carolina
110-Cutting Edge Research Group
Oklahoma City, Oklahoma
170-Suburban Research Associates
Downingtown, Pennsylvania
127-University Hills Clinical Research
Irving, Texas
103-Pillar Clinical Research, LLC
Richardson, Texas
115-Psychiatric and Behavioral Solutions LLC
Salt Lake City, Utah
610-Clinica Privada Banfield S.A.
Buenos Aires, Argentina
625-NOVAIN Neurociencias Group
Buenos Aires, Argentina
603-Fundación para el Estudio y Tratamiento de las Enfermedades Mentales - FETEM
Ciudad Autonoma Buenos Aires, Argentina
601-CENydET- Centro Neurobiologico y de Estres Traumatico-Biopsychomedical Research Group SRL
Ciudad Autonoma de Buenos Aire, Argentina
602-FunDamoS
Ciudad Autonoma de Buenos Aire, Argentina
622-Instituto Medico Damic Srl
Córdoba, Argentina
624-Centro Especializado en Neurociencias CEN
Córdoba, Argentina
626-Sanatorio Prof. Leon S. Morra S.A.
Córdoba, Argentina
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.